Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold.
Dodd, D.S., Sheriff, S., Chang, C.J., Stetsko, D.K., Phillips, L.M., Zhang, Y., Launay, M., Potin, D., Vaccaro, W., Poss, M.A., McKinnon, M., Barrish, J.C., Suchard, S.J., Murali Dhar, T.G.(2007) Bioorg Med Chem Lett 17: 1908-1911
- PubMed: 17291752 
- DOI: https://doi.org/10.1016/j.bmcl.2007.01.036
- Primary Citation of Related Structures:  
2O7N - PubMed Abstract: 
A new class of lymphocyte function-associated antigen-1 (LFA-1) antagonists is described. Elaboration of the 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold resulted in the synthesis of potent inhibitors of the LFA-1/ICAM-1 interaction. Along with the in vitro activity, we present the X-ray crystal structure of the complex of compound 9b, in a novel binding mode to the I-domain of LFA-1.
Organizational Affiliation: 
Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, NJ 08543-4000, USA. dharmpal.dodd@bms.com